Loading...
DOCUMENTS
21
NOTICES
32
MOTS CLES
Rituximab
Kidney diseases
Heart disease risk factors
Inclusion
Immune cells
Colectomy
Survival
Therapeutics
Clinical trial
Crohn's disease
Methylation
Eradication
Tailored therapy
Helicobacter pylori
Drug
Thérapie ciblée
Biomarker
Colorectal cancer
Intestinal crypts
Patients experience
Stricture
Acceptability
Ulcerative colitis
Inflammatory bowel diseases
Gene methylation
Resistance
Monitoring
Gènes
Disease progression
Anti-TNF
Colon cancer
Microbiota
Anti-TNF agents
Effectiveness
Upper gastrointestinal tract
Rituximab plus chlorambucil
Primary sclerosing cholangitis
CARCINOGENESIS
COLON-CANCER
Colon
Biologics
Cancer
Dysbiose
Vedolizumab
Surgery
Screening
PCR
Contraindication
Genes
Epigénétiques
MORTALITY
DNA methylation
Over 80s
Bactéries
Maintenance therapy
Tuberculosis
Endoscopic treatment
18 FDG-PET/CT
Gene expression
Microbiote
Neoadjuvant chemotherapy
Disability
T1118 translocation
MICROBIOTA
Résistance
Inflammatory bowel disease
Parvimonas micra
Eligibility
Cell adhesion
Clinical guidelines
Safety
Inhibitor
Original Article Clinical
Patient-reported outcome
RISK
Ustekinumab
MALT
Disease Progression
IL12
IL23
DNA METHYLATION
Epigenetics
Venous thromboembolism
Colonic epithelial primary cells
Colorectal cancer Colibactin and lipids
Consensus
Fecal microbiota
Bacteria
MARKER
IBD
Algorithm
Méthylation
Inflammatory Bowel Diseases
Alkylating agents
Cost effectiveness
Crohn’s disease
Dysbiosis
HIV
Small molecules
Immunosuppressant
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|